<div><h3>Background</h3><p>The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% reduction in mortality. However, CT screening has a number of disadvantages including low specificity. A validated autoantibody assay is available commercially (<em>Early</em>CDT®-Lung) to aid in the early detection of lung cancer and risk stratification in patients with pulmonary nodules detected by CT.</p> <p>Recent advances in high throughput (HTP) cloning and expression methods have been developed into a discovery pipeline to identify biomarkers that detect autoantibodies. The aim of this study was to demonstrate the successful clinical application of this strategy to add to the <em>Early</em>CDT-Lung panel in order to impr...
Lung cancer has the highest mortality rate among cancer patients in the world, in particular because...
Abstract Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, an...
Background: The majority (around 80%) of cases of lung cancer are detected at a late stage when prog...
The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% reduction in...
BACKGROUND: The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% ...
An assay employing a panel of tumor-associated antigens has been validated and is available commerci...
Lung cancer has the highest mortality rate among cancer patients in the world, in particular because...
Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, and the Ear...
ObjectivesEarlyCDT®-Lung may enhance detection of early stage lung cancer by aiding physicians in as...
Background: Lung cancer is the most common cause of cancer related death worldwide. The majority of ...
CDT-Lung panel in order to improve its sensitivity and specificity (and hence positive predictive va...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...
The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribut...
AbstractObjectivesEarlyCDT®-Lung may enhance detection of early stage lung cancer by aiding physicia...
Lung cancer has the highest mortality rate among cancer patients in the world, in particular because...
Abstract Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, an...
Background: The majority (around 80%) of cases of lung cancer are detected at a late stage when prog...
The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% reduction in...
BACKGROUND: The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% ...
An assay employing a panel of tumor-associated antigens has been validated and is available commerci...
Lung cancer has the highest mortality rate among cancer patients in the world, in particular because...
Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, and the Ear...
ObjectivesEarlyCDT®-Lung may enhance detection of early stage lung cancer by aiding physicians in as...
Background: Lung cancer is the most common cause of cancer related death worldwide. The majority of ...
CDT-Lung panel in order to improve its sensitivity and specificity (and hence positive predictive va...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...
The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribut...
AbstractObjectivesEarlyCDT®-Lung may enhance detection of early stage lung cancer by aiding physicia...
Lung cancer has the highest mortality rate among cancer patients in the world, in particular because...
Abstract Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, an...
Background: The majority (around 80%) of cases of lung cancer are detected at a late stage when prog...